Practical Guidance
Time-saving Solutions
Knowledgeable Insights

AHLA Pharmaceutical and Medical Device Compliance Manual (FDLI)

The AHLA Pharmaceutical and Medical Device Compliance Manual includes Federal Anti-Kickback Statute and False Claims Act details as well as guidance on building your compliance program.
Publisher: AHLA
Book + CD :Softbound with CD-ROM, 350 pages
1st Edition
$158.00
Quantity
In Stock
ISBN: 9780769860114
Publisher: AHLA
International Order Inquiry

Product details

If you are not an FDLI member and would like to purchase this book, click here.
Seton Hall click here.

The fight against fraud and abuse in healthcare programs, and the pharmaceutical and medical devices industry in particular, continues to grow. Since 1996 the federal government has strengthened its efforts to detect and prevent fraud and abuse in healthcare, and has recovered $18 billion since 1997. These enforcement activities make a compliance program essential to protecting a company from running afoul of the myriad laws and regulations that have been enacted to combat fraud and waste. Pharmaceutical and Medical Device Compliance Manual includes guidance to help companies do that.

Coverage includes:

•  In-depth coverage of the federal and state enforcement agencies
•  Federal Anti-Kickback Statute and False Claims Act details
•  Distinction between manufacturers' lawful dissemination of scientific information and unlawful promotion of off-label use
•  Discussion of the Foreign Corrupt Practices Act and its extra-territorial reach
•  Coverage and reimbursement of prescription drugs and medical devices
•  Prescription drug price regulations

The Manual includes guidance on building an effective compliance program and will be a great tool for health and life sciences attorneys, compliance officers, and others in the pharmaceutical and medical devices industry.

EDITORS

Kathleen M. Boozang, J.D., LL.M.,
Professor of Law, SETON HALL | LAW, Center for Health & Pharmaceutical Law & Policy, Newark, NJ
Simone Handler-Hutchinson, J.D., Executive Director, SETON HALL | LAW, Center for Health & Pharmaceutical Law & Policy, Newark, NJ

CONTRIBUTING AUTHORS

Bret A. Campbell, Esquire;
Cadwalader, Wickersham & Taft LLP, Washington, DC; Sujata Dayal, Esquire; Biomet, Inc., Warsaw, IN; Michael Andre Donnella, Esquire; Wyeth, Madison, NJ; Katie Rose Fink, Esquire; U.S. Dept. of Health & Human Services, Office of Inspector General, Washington, DC; Brett R. Friedman, Esquire; Ropes & Gray, LLP, New York. NY; Gary F. Giampetruzzi, Esquire; Pfizer, Inc., New York, NY; Christopher R. Hall, Esquire; Saul Ewing, LLP, Philadelphia, PA; Patrick M. Hromisin, Esquire; Saul Ewing, LLP, Philadelphia, PA; Elizabeth H. Kim, Esquire; Porzio Life Sciences, LLC, Morristown, NJ; Daniel A. Kracov, Esquire; Arnold & Porter, LLP; Washington, DC; Bruce A. Levy, Esquire; Gibbons, PC., Newark, NJ; Ann E. Lewis, Esquire; Ropes & Gray, LLP, New York. NY; Benjamin S. Martin, Esquire; Epstein Becker & Green, PC, Washington, DC; Joseph W. Metro, Esquire; Reed Smith, LLP, Washington, DC; Lewis Morris, Esquire; U.S. Dept. of Health & Human Services, Office of Inspector General, Washington, DC; Kiaema R. Reid; Porzio Life Sciences, LLC, Morristown, NJ; Linda Pissott Reig, Esquire; Buchanan Ingersoll & Rooney, PC, Newark, NJ; Margaret Renner, Esquire; FDA (formerly Arnold & Porter), Silver Spring, MD; Mary Riordan, Esquire; U.S. Dept. of Health & Human Services, Office of Inspector General, Washington, DC; Lynn Shapiro Snyder, Esquire; Epstein Becker & Green, PC, Washington, DC; Brian Tretick; Athena Privacy, LLC, Washington, DC; Robert E. Wanerman, Esquire; Epstein Becker & Green, PC, Washington, DC; and Mara E. Zazzali-Hogan, Esquire, Gibbons, PC., Newark, NJ

Table of Contents

Table of Contents



Preface

About the Authors

Introduction



1    Enforcement Authorities

2    Thou Shalt Not Buy Business: The Implications of the Anti-Kickback Statute on the Drug and Device Industry

3    False Claims Act

4    Advertising, Labeling, and Promotion

5    Drug and Device Development and Approval

6    Federal Healthcare Programs: Coverage and Reimbursement of Prescription Drugs and Medical Devices

7    Foreign Corrupt Practices Act

8    Privacy and Data Protection

9    Sunny Side Up: A New Era of State and Federal Aggregate Spend and Marketing Disclosure Laws

10    Elements of an Effective Compliance Program

11    Prescription Drug Price Regulation: Key Considerations for Compliance Officers



Compliance Glossary



Index